Amgen nabs Kyprolis OK in Europe as U.S. competition mounts

It's been more than three years since Amgen's ($AMGN) multiple myeloma treatment Kyprolis won approval from U.S. regulators. Now, it's finally done the same in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time for the California biotech. Earlier this month, it picked up a new competitor in its home market in Johnson & Johnson's ($JNJ) Darzalex. And though that med will come after both Kyprolis and Celgene rival Pomalyst in the disease course, J&J will be armed with data showing that 36% of patients responded to the top dose of Darzalex in a small study, a number that tops Kyprolis' 23%. More from FiercePharmaMarketing

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.